Development of a Scalable Synthesis for the Potent Kinase Inhibitor BMS-986236; 1‑(5-(4-(3-Hydroxy-3-methylbutyl)‑1H‑1,2,3-triazol-1-yl)-4-(isopropylamino)pyridin-2-yl)‑1H‑pyrazolo[3,4‑b]pyridine-5-carbonitrile

A scalable route to 1-(5-(4-(3-hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-4-(isopropylamino)­pyridin-2-yl)-1H-pyrazolo­[3,4-b]­pyridine-5-carbonitrile (1, BMS-986236) was developed by incorporating an alternate azide intermediate following safety-driven processes. The newly developed process involved mitigating safety hazards and eliminating the column chromatography purification. The issue of trace metal contamination in the final API observed in the first-generation synthesis has been overcome.